Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registry.

Iversen AZ, Pedersen SH, Joens C, Mogelvang R, Galatius S, Galloe A, Abildgaard U, Hansen PR, Madsen JK, Jensen JS.

J Invasive Cardiol. 2011 Jan;23(1):21-6.

2.

Impact of abciximab in elderly patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention: an observational registry study.

Iversen AZ, Galatius S, Pedersen S, Madsen JK, Jensen JS.

Drugs Aging. 2011 May 1;28(5):369-78. doi: 10.2165/11587170-000000000-00000.

PMID:
21542659
3.

Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.

Roffi M, Moliterno DJ, Meier B, Powers ER, Grines CL, DiBattiste PM, Herrmann HC, Bertrand M, Harris KE, Demopoulos LA, Topol EJ; TARGET Investigators.

Circulation. 2002 Jun 11;105(23):2730-6.

4.

Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.

Kleiman NS, Lincoff AM, Kereiakes DJ, Miller DP, Aguirre FV, Anderson KM, Weisman HF, Califf RM, Topol EJ.

Circulation. 1998 May 19;97(19):1912-20.

5.

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.

Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ.

Circulation. 1999 Dec 21-28;100(25):2477-84.

6.

Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.

Ibbotson T, McGavin JK, Goa KL.

Am J Cardiovasc Drugs. 2003;3(5):381-6. Review.

PMID:
14728074
7.

Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation.

Velianou JL, Mathew V, Wilson SH, Barsness GW, Grill DE, Holmes DR Jr.

Am J Cardiol. 2000 Nov 15;86(10):1063-8.

PMID:
11074200
8.

Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.

Kastrati A, Mehilli J, Neumann FJ, Dotzer F, ten Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schühlen H, Dirschinger J, Berger PB, Schömig A; Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators.

JAMA. 2006 Apr 5;295(13):1531-8. Epub 2006 Mar 13.

PMID:
16533938
9.

Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ.

J Am Coll Cardiol. 2000 Mar 15;35(4):922-8.

10.

Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.

Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ.

N Engl J Med. 1999 Jul 29;341(5):319-27.

12.

Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.

Circulation. 1999 Apr 20;99(15):1951-8.

13.

Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

Akerblom A, James SK, Koutouzis M, Lagerqvist B, Stenestrand U, Svennblad B, Oldgren J.

J Am Coll Cardiol. 2010 Aug 3;56(6):470-5. doi: 10.1016/j.jacc.2009.10.093.

14.

Long-term results following switch from abciximab to eptifibatide during percutaneous coronary intervention.

Koutouzis M, Lagerqvist B, Oldgren J, Akerblom A, Wahlin M, Karlsson T, Albertsson P, Matejka G, Grip L.

Clin Cardiol. 2010 Nov;33(11):686-92. doi: 10.1002/clc.20814.

15.
16.

Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.

Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators.

Circulation. 2004 Dec 14;110(24):3627-35. Epub 2004 Nov 7.

17.

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.

Tcheng JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, Mehran R, Stone GW; CADILLAC Investigators.

Circulation. 2003 Sep 16;108(11):1316-23. Epub 2003 Aug 25.

18.

Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.

Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E.

J Am Coll Cardiol. 2010 Aug 3;56(6):463-9. doi: 10.1016/j.jacc.2009.08.093.

19.

[Does abciximab improve the prognosis of diabetics after percutaneous coronary intervention?].

Hernández García JM, Domínguez Franco A, Jiménez-Navarro MF, Alonso Briales JH, Curiel Balsera E, Gómez Doblas JJ, De Teresa Galván E.

Rev Esp Cardiol. 2002 Aug;55(8):810-5. Spanish.

20.

Evaluation of the role of abciximab (Reopro) as a rescue agent during percutaneous coronary interventions: in-hospital and six-month outcomes.

Velianou JL, Strauss BH, Kreatsoulas C, Pericak D, Natarajan MK.

Catheter Cardiovasc Interv. 2000 Oct;51(2):138-44.

PMID:
11025564

Supplemental Content

Support Center